 ISELIN, N.J., May 18, 2022 GLOBE NEWSWIRE -- Outlook Therapeutics, Inc. Nasdaq: OTLK, a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually. 